| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 临床前研究服务(元) | 40,871,230.19 | 84,318,881.08 | 41,795,073.84 | 78,290,291.27 | 28,591,142.64 |
| 临床研究服务(元) | 289,794,388.07 | 597,383,536.71 | 271,384,282.64 | 414,510,164.45 | 173,847,970.66 |
| 技术成果转化服务(元) | - | - | - | - | - |
| 临床前自主研发(元) | - | - | - | 253,788.67 | - |
| 其他咨询服务(元) | 23,491,645.67 | 42,219,135.42 | 17,824,877.42 | 48,538,636.28 | 23,137,684.12 |
| 营业成本(元) | |||||
| 临床前研究服务(元) | 30,177,244.10 | 65,875,769.43 | 30,163,555.50 | 62,766,684.88 | 18,868,812.80 |
| 临床研究服务(元) | 201,013,179.89 | 418,481,048.45 | 186,615,965.06 | 279,045,573.36 | 116,474,162.93 |
| 技术成果转化服务(元) | - | - | - | - | - |
| 临床前自主研发(元) | - | - | - | - | - |
| 其他咨询服务(元) | 12,519,176.01 | 21,306,995.84 | 9,051,146.78 | 23,096,434.67 | 9,764,424.70 |
| 毛利(元) | |||||
| 临床前研究服务(元) | 10,693,986.09 | 18,443,111.65 | 11,631,518.34 | 15,523,606.39 | 9,722,329.84 |
| 临床研究服务(元) | 88,781,208.18 | 178,902,488.26 | 84,768,317.58 | 135,464,591.09 | 57,373,807.73 |
| 技术成果转化服务(元) | - | - | - | - | - |
| 临床前自主研发(元) | - | - | - | - | - |
| 其他咨询服务(元) | 10,972,469.66 | 20,912,139.58 | 8,773,730.64 | 25,442,201.61 | 13,373,259.42 |
| 毛利率(%) | |||||
| 临床前研究服务(%) | 26.17 | 21.87 | 27.83 | 19.83 | 34.00 |
| 临床研究服务(%) | 30.64 | 29.95 | 31.24 | 32.68 | 33.00 |
| 技术成果转化服务(%) | - | - | - | - | - |
| 临床前自主研发(%) | - | - | - | - | - |
| 其他咨询服务(%) | 46.71 | 49.53 | 49.22 | 52.42 | 57.80 |
| 收入构成(%) | |||||
| 临床前研究服务(%) | 11.54 | 11.65 | 12.63 | 14.46 | 12.67 |
| 临床研究服务(%) | 81.83 | 82.52 | 81.99 | 76.54 | 77.07 |
| 技术成果转化服务(%) | - | - | - | 0.00 | - |
| 临床前自主研发(%) | - | 0.00 | - | 0.05 | - |
| 其他咨询服务(%) | 6.63 | 5.83 | 5.39 | 8.96 | 10.26 |
| 毛利构成(%) | |||||
| 临床前研究服务(%) | 9.68 | 8.45 | 11.06 | 8.80 | 12.08 |
| 临床研究服务(%) | 80.38 | 81.97 | 80.60 | 76.78 | 71.30 |
| 技术成果转化服务(%) | - | - | - | 0.00 | - |
| 临床前自主研发(%) | - | 0.00 | - | 0.00 | - |
| 其他咨询服务(%) | 9.93 | 9.58 | 8.34 | 14.42 | 16.62 |